Effectiveness and Persistence in SB4 and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.
Glenn HaugebergGunnstein BaklandErik RødevandInger Johanne Widding HansenAndreas P DiamantopoulosAre Hugo PrippPublished in: Arthritis care & research (2023)
Outcomes for disease status/drug persistence at W52 were similar between patients with RA treated with etanercept or SB4. This article is protected by copyright. All rights reserved.
Keyphrases
- rheumatoid arthritis patients
- disease activity
- rheumatoid arthritis
- clinical practice
- systemic lupus erythematosus
- ankylosing spondylitis
- randomized controlled trial
- juvenile idiopathic arthritis
- systematic review
- emergency department
- newly diagnosed
- type diabetes
- interstitial lung disease
- adipose tissue
- metabolic syndrome
- systemic sclerosis
- weight loss
- electronic health record